AstraZeneca and Oracle adopt AI for faster trials

AstraZeneca announced its collaboration with Oracle to utilize artificial intelligence and real-world data with the aim of improving the selection of the most suitable patients for clinical trials. This partnership seeks to enhance the accuracy and efficiency of patient selection processes and reduce the time required to conduct trials, thereby accelerating drug development and providing more effective treatments.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل